Union Savings Bank Makes New $1.09 Million Investment in Johnson & Johnson $JNJ

Key Points

• Union Savings Bank opened a new position in Johnson & Johnson during the fourth quarter, buying 5,293 shares worth about $1.09 million.
• Wall Street sentiment remains broadly positive: analysts cite multiple buy/outperform ratings, with 20 Buy and 7 Hold ratings overall and an average target price of $253.04.
• Johnson & Johnson recently raised its dividend to $1.34 per quarter and posted stronger-than-expected quarterly earnings and revenue, although the stock has been relatively soft recently.

Union Savings Bank purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,293 shares of the company's stock, valued at approximately $1,095,000.

Other hedge funds have also recently bought and sold shares of the company. Redwood Family Wealth LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth about $494,000. Cedarwood Wealth LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $289,000. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $249,000. Mengis Capital Management Inc. boosted its holdings in shares of Johnson & Johnson by 13.7% during the fourth quarter. Mengis Capital Management Inc. now owns 40,972 shares of the company's stock worth $8,479,000 after purchasing an additional 4,922 shares during the period. Finally, Bayban purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $1,614,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on JNJ shares. Royal Bank Of Canada reiterated an "outperform" rating and issued a $265.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Argus increased their price objective on Johnson & Johnson from $240.00 to $275.00 and gave the stock a "buy" rating in a report on Thursday, April 16th. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the company a "neutral" rating in a research report on Wednesday, April 15th. Citigroup boosted their target price on Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a research note on Tuesday, April 7th. Finally, Weiss Ratings lowered Johnson & Johnson from a "buy (b)" rating to a "buy (b-)" rating in a research report on Monday, June 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $253.04.

Insiders Place Their Bets

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 0.0%

JNJ stock opened at $228.37 on Friday. The firm has a market cap of $549.73 billion, a PE ratio of 26.40, a PEG ratio of 2.24 and a beta of 0.26. Johnson & Johnson has a 1 year low of $149.04 and a 1 year high of $251.71. The company has a fifty day simple moving average of $230.61 and a 200 day simple moving average of $228.09. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the prior year, the business posted $2.77 earnings per share. The business's quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio (DPR) is 61.97%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s prostate cancer drug Erleada showed encouraging clinical results, with Reuters-reported data indicating it cut the risk of cancer spread or death by 20% in a study setting. That kind of pipeline progress can support longer-term revenue growth. Article Title
• Positive Sentiment: The company continues to be highlighted as a strong dividend stock, with articles pointing to Johnson & Johnson’s long history of dividend increases and its appeal to income-focused investors seeking stability in a volatile market. Article Title
• Positive Sentiment: Johnson & Johnson announced plans to invest more than $1 billion in a Florida contact lens manufacturing facility, reinforcing confidence in future operating capacity and U.S. production investment. Article Title
• Neutral Sentiment: Several commentary pieces describe JNJ as a defensive name that may hold up better if markets weaken, but these articles are largely opinion-based and do not add new fundamental catalysts. Article Title
• Negative Sentiment: Shares have been soft over the past few months, with one note saying the stock is down about 3% in three months despite solid results and pipeline progress. That recent weakness may be weighing on sentiment even as investors debate whether the dip is attractive. Article Title

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.